KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Biogen (BIIB) EBT (2016 - 2025)

Historic EBT for Biogen (BIIB) over the last 17 years, with Q4 2025 value amounting to -$56.0 million.

  • Biogen's EBT fell 11921.1% to -$56.0 million in Q4 2025 from the same period last year, while for Dec 2025 it was $1.6 billion, marking a year-over-year decrease of 1833.68%. This contributed to the annual value of $1.6 billion for FY2025, which is 1833.68% down from last year.
  • Per Biogen's latest filing, its EBT stood at -$56.0 million for Q4 2025, which was down 11921.1% from $557.3 million recorded in Q3 2025.
  • Biogen's EBT's 5-year high stood at $1.4 billion during Q3 2022, with a 5-year trough of -$141.2 million in Q3 2023.
  • In the last 5 years, Biogen's EBT had a median value of $457.9 million in 2024 and averaged $504.8 million.
  • Its EBT has fluctuated over the past 5 years, first skyrocketed by 41940.51% in 2024, then plummeted by 11921.1% in 2025.
  • Quarter analysis of 5 years shows Biogen's EBT stood at $405.0 million in 2021, then soared by 49.09% to $603.8 million in 2022, then crashed by 51.71% to $291.6 million in 2023, then decreased by 0.03% to $291.5 million in 2024, then plummeted by 119.21% to -$56.0 million in 2025.
  • Its EBT stands at -$56.0 million for Q4 2025, versus $557.3 million for Q3 2025 and $744.0 million for Q2 2025.